Antibody-Drug Conjugates (ADCs), as a part of precision medicine, target tumor cells by combining the specificity of antibodies with the potent effects of cytotoxins.
The European Medicines Agency has accepted Bristol Myers Squibb's application for CAR T cell therapy Breyanzi for treating relapsed or refractory follicular lymphoma.
Aug 21st latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
This trial aims to evaluate the safety and tolerability of MOMA-313, an innovative and highly potent, selective oral inhibitor targeting polymerase theta helicase.
The proposal seeks regulatory approval under the TGA’s Clinical Trial Notification (CTN) scheme to initiate a first-in-human Phase 1 clinical trial for SAT-3247.
The EMA has accepted a Type II Variation Application for ENHERTU® to treat patients with HER2 low or ultralow metastatic breast cancer after at least one endocrine therapy.
NewBridge will have exclusive distribution rights in Algeria, Iraq, Libya, and Jordan for CRYSVITA® (burosumab) for the treatment of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO).